A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

The entry queue has surged while the exit line continues to shrink, potentially nearing zero in the coming days. Ethereum’s staking dynamics have shifted sharply, with fresh inflows now outpacing ...

Electrical substation infrastructure increasingly sits at the front of data center project planning as utilities tighten grid access and require major power upgrades ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

A controlled test compared three nearly identical pages: one with strong schema, one with poor schema, and one with none. Only the page with well-implemented schema appeared in an AI Overview and ...

Section 1. Policy and Purpose. My Administration has inaugurated a golden age for American manufacturing and technological dominance. We will pursue bold, large-scale industrial plans to vault the ...

Data structures contain two important aspects that computer scientists seek to verify: behavior and cost. The behavior of data structures has long been studied using abstraction functions, which ...

PDVSA launches Blend 22 exports ahead of May 27 license expiry New crude blend being shipped from Western La Salina port Vitol-chartered vessel's hull being cleaned after loading at La Salina Loading ...

Structure content for AI search so it’s easy for LLMs to cite. Use clarity, formatting, and hierarchy to improve your visibility in AI results. In the SEO world, when we talk about how to structure ...

Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...